ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...

SE recently presented new clinical data at the 2026 American Academy of Neurology meeting, showing VYVGART’s efficacy in ocular myasthenia gravis, broader generalized MG subtypes, and chronic ...

The FDA on March 16 approved CSL Behring’s drug Hizentra to treat chronic inflammatory demyelinating polyneuropathy. Hizentra is the first subcutaneous immunoglobulin approved to treat CIDP, a rare ...

(ENXTBR:ARGX) is back in focus after presenting new VYVGART data at the 2026 American Academy of Neurology meeting, highlighting efficacy in ocular myasthenia gravis and early clinical benefit signals ...

CEO Tim Van Hauwermeiren emphasized 2024 as a "phenomenal year," highlighted by expanding the reach of VYVGART to over 10,000 patients globally across three approved indications. He noted the ...

Folia Health today announced a collaboration with argenx to launch a first-of-its-kind, at-home observational real-world evidence initiative supporting individuals living with chronic inflammatory ...

WAYNE, Pennsylvania (WPVI) -- One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get back on their feet. A great place to see their ...

MONTREAL — An open-label extension study of subcutaneous efgartigimod PH20 to treat chronic inflammatory demyelinating polyneuropathy (CIDP) showed durability of functional improvements to week 24, ...

(RTTNews) - argenx SE (ARGX), Wednesday, announced that Health Canada has issued a Notice of Compliance authorizing VYVGART SC as a monotherapy for the treatment of adult patients with active chronic ...

The US Food and Drug Administration (FDA) has approved a prefilled syringe for self-injection of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) in the treatment of adults with ...